Clal Biotechnology Industries

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, focused on advancing blood diagnostics through the integration of machine vision and artificial intelligence. The company has developed a platform that utilizes digital fluorescent microscopy and computer vision algorithms to diagnose various blood diseases. Its flagship product, Parasight, is designed for malaria detection and has been used in nearly one million tests across 24 countries, although it is not available for sale in the United States. Additionally, Sight Diagnostics has introduced the Sight OLO, a blood analyzer that requires only two drops of blood from a finger prick or venous sample to deliver lab-grade Complete Blood Count results within minutes. With a presence in the UK, the US, and Israel, Sight Diagnostics is expanding its commercial footprint across five continents, aiming to enhance healthcare through fast and accurate blood testing solutions.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Elicio Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of amphiphile immunotherapies aimed at treating aggressive cancers. The company leverages its proprietary Amphiphile platform to deliver immunogens directly to the lymphatic system, enhancing the immune response and improving the body’s ability to fight cancer. Elicio's key products include ELI-002, an amphiphile vaccine targeting KRAS gene mutations to prevent recurrence in pancreatic, colorectal, and lung cancers, and ELI-001, which is designed for HPV-driven head and neck cancers. Elicio Therapeutics was founded in 2011 and was previously known as Vedantra Pharmaceuticals before rebranding in 2019. The company focuses on creating innovative immunotherapies for patients with limited treatment options and challenging cancer types.

Anchiano Therapeutics Ltd. is a preclinical biotechnology company based in Cambridge, Massachusetts, that focuses on discovering, developing, and commercializing small molecule anti-cancer therapies. The company primarily works on the Pan-RAS Program, which aims to develop novel indene-based small molecules that inhibit activated RAS signaling across various isoforms and mutations. Additionally, Anchiano is advancing a PDE10/ß-catenin program targeting small molecules that selectively inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling. The company has established a collaboration and license agreement with ADT Pharmaceuticals to further research these programs. Founded in 2004 and originally known as BioCancell Ltd., Anchiano Therapeutics aims to provide targeted cancer therapies that selectively destroy cancer cells while sparing healthy cells, utilizing specific gene expressions found predominantly in tumors. Its lead drug candidate, BC-819, has completed a Phase IIb clinical trial for bladder cancer, with ongoing investigations into other cancer types.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, that specializes in developing innovative solutions for colorectal surgeries. Founded in 2010, the company has created proprietary technology aimed at preventing anastomotic leaks and minimizing the need for diverting colonic stomas. Its lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site after procedures such as colectomy, which is often necessary in cases of severe intestinal inflammatory diseases and bowel or rectal cancer. By addressing the risk of leakage that can lead to prolonged hospitalization or additional surgeries, Colospan's devices aim to improve patient outcomes and facilitate a smoother recovery process while mitigating post-operative complications.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Pi-Cardia is a medical device start-up focused on developing an innovative catheter designed to treat aortic stenosis. The company’s proprietary technology utilizes a low-profile trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissues. This procedure, which takes only a few seconds, aims to increase the effective orifice area of the valve, providing a less invasive alternative to valve replacement. Pi-Cardia's approach seeks to offer a cost-effective and durable treatment option for patients suffering from this condition.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, focused on advancing blood diagnostics through the integration of machine vision and artificial intelligence. The company has developed a platform that utilizes digital fluorescent microscopy and computer vision algorithms to diagnose various blood diseases. Its flagship product, Parasight, is designed for malaria detection and has been used in nearly one million tests across 24 countries, although it is not available for sale in the United States. Additionally, Sight Diagnostics has introduced the Sight OLO, a blood analyzer that requires only two drops of blood from a finger prick or venous sample to deliver lab-grade Complete Blood Count results within minutes. With a presence in the UK, the US, and Israel, Sight Diagnostics is expanding its commercial footprint across five continents, aiming to enhance healthcare through fast and accurate blood testing solutions.

CureTech Ltd. is a biotechnology company based in Yavne, Israel, specializing in the development of immune modulating products for cancer treatment and control. Founded in 2001, the company focuses on creating novel antibodies and peptide-based therapeutics designed to enhance the immune response against cancer. One of its key products is pidilizumab, a humanized monoclonal antibody that has demonstrated effectiveness in eliciting an anti-cancer immune response across various types of tumors, including pediatric brain cancer. CureTech aims to address tumor growth and metastasis through its innovative therapeutic approaches.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative diagnostic and therapeutic drugs. Established in 1996, Aposense specializes in utilizing its patented platform technology to target apoptosis, or programmed cell death, which enables real-time imaging of disease activity and the development of targeted therapies. The company innovates in gene therapy by creating transport molecules that facilitate the introduction of genetic material, particularly small interfering RNA (siRNA), through biological membranes. Aposense is also known for its molecular nano-motors, which are designed to harness electrical properties of membranes for drug delivery, including its development of ATT-11T, a conjugate aimed at treating solid tumors.

Polyheal Ltd. is an advanced medical device company based in Yavne, Israel, specializing in wound care solutions. Founded in 1996, it develops and manufactures a sterile liquid suspension that employs negatively-charged microsphere (NCM) technology to treat a variety of challenging wounds. This innovative product is designed for chronic wounds, such as diabetic foot ulcers, pressure ulcers, and post-surgical complications, as well as wounds with exposed bone and foreign materials. Polyheal's technology promotes the wound healing process without the use of pharmacologically active agents, utilizing chemically inert, non-biodegradable microspheres. In addition to its product offerings, the company provides training and education services to enhance the effective use of its technology. Polyheal primarily serves patients across Europe and Israel.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.